{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:13:24Z","timestamp":1792826004024,"version":"4.5.0"},"reference-count":226,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Context.<\/jats:italic>\n                    \u2014Pathogen inactivation provides a proactive approach to cleansing the blood supply. In the plasma fractionation and manufacturing industry, pathogen inactivation technologies have been successfully implemented resulting in no transmission of human immunodeficiency, hepatitis C, or hepatitis B viruses by US-licensed plasma derivatives since 1985. However, these technologies cannot be used to pathogen inactivate cellular blood components. Although current blood donor screening and disease testing has drastically reduced the incidence of transfusion-transmitted diseases, there still looms the threat to the blood supply of a new or reemerging pathogen. Of particular concern is the silent emergence of a new agent with a prolonged latent period in which asymptomatic infected carriers would donate and spread infection.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Objective.<\/jats:italic>\n                    \u2014To review and summarize the principles, challenges, achievements, prospective technologies, and future goals of pathogen inactivation of the blood supply.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Data Sources.<\/jats:italic>\n                    \u2014The current published English-language literature from 1968 through 2006 and a historical landmark article from 1943 are integrated into a review of this subject.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Conclusions.<\/jats:italic>\n                    \u2014The ultimate goal of pathogen inactivation is to maximally reduce the transmission of potential pathogens without significantly compromising the therapeutic efficacy of the cellular and protein constituents of blood. This must be accomplished without introducing toxicities into the blood supply and without causing neoantigen formation and subsequent antibody production. Several promising pathogen inactivation technologies are being developed and clinically tested, and others are currently in use. Pathogen inactivation offers additional layers of protection from infectious agents that threaten the blood supply and has the potential to impact the safety of blood transfusions worldwide.\n                  <\/jats:p>","DOI":"10.5858\/2007-131-719-pitdsf","type":"journal-article","created":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T20:56:26Z","timestamp":1613076986000},"page":"719-733","source":"Crossref","is-referenced-by-count":63,"title":["Pathogen Inactivation: The Definitive Safeguard for the Blood Supply"],"prefix":"10.5858","volume":"131","author":[{"given":"Barbara J.","family":"Bryant","sequence":"first","affiliation":[{"name":"From the Department of Transfusion Medicine, National Institutes of Health, Bethesda, Md"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey G.","family":"Klein","sequence":"additional","affiliation":[{"name":"From the Department of Transfusion Medicine, National Institutes of Health, Bethesda, Md"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"key":"i1543-2165-131-5-719-b1","series-title":"JAMA","first-page":"1332","article-title":"Jaundice occurring one to four months after transfusion of blood or plasma\u2014report of seven cases.","volume":"121","author":"Beeson, P. B.","year":"1943","unstructured":"Beeson, P. B.\n          \n          Jaundice occurring one to four months after transfusion of blood or plasma\u2014report of seven cases.\n          JAMA\n          1943. 121:1332\u20131334."},{"key":"i1543-2165-131-5-719-b2","series-title":"Transfusion","first-page":"975","article-title":"Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood door population.","volume":"42","author":"Dodd, R. Y.","year":"2002","unstructured":"Dodd, R. Y., E. P.Notari, and S. L.Stramer. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood door population.Transfusion2002. 42:975\u2013979."},{"key":"i1543-2165-131-5-719-b3","series-title":"Ann Intern Med","first-page":"537","article-title":"Meeting transfusion safety expectations.","volume":"143","author":"AuBuchon, J. P.","year":"2005","unstructured":"AuBuchon, J. P.\n          \n          Meeting transfusion safety expectations.\n          Ann Intern Med\n          2005. 143:537\u2013538."},{"key":"i1543-2165-131-5-719-b4","series-title":"N Engl J Med","first-page":"438","article-title":"Transfusion medicine: first of two parts\u2014blood transfusion.","volume":"340","author":"Goodnough, L. T.","year":"1999","unstructured":"Goodnough, L. T., M. E.Brecher, M. H.Kanter, and J. P.AuBuchon. Transfusion medicine: first of two parts\u2014blood transfusion.N Engl J Med1999. 340:438\u2013447."},{"key":"i1543-2165-131-5-719-b5","series-title":"Haema","first-page":"24","article-title":"Transfusion-transmitted infections: epidemiology, risks and prevention.","volume":"4","author":"Theodossiades, G.","year":"2001","unstructured":"Theodossiades, G. and M.Makris. Transfusion-transmitted infections: epidemiology, risks and prevention.Haema2001. 4:24\u201338."},{"key":"i1543-2165-131-5-719-b6","series-title":"Transfus Clin Biol","first-page":"81","article-title":"Trends in residual risk of transfusion transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (nucleic acid testing).","volume":"11","author":"Pillonel, J.","year":"2004","unstructured":"Pillonel, J. and S.Laperche. Trends in residual risk of transfusion transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (nucleic acid testing).Transfus Clin Biol2004. 11:81\u201386."},{"key":"i1543-2165-131-5-719-b7","series-title":"MMWR Weekly","first-page":"281","article-title":"Update: West Nile virus screening of blood donations and transfusion-associated transmission\u2014United States, 2003.","volume":"53","year":"April 9, 2004","unstructured":"Centers for Disease Control and Prevention.\n          \n          Update: West Nile virus screening of blood donations and transfusion-associated transmission\u2014United States, 2003.\n          MMWR Weekly\n          April 9, 2004. 53:281\u2013284."},{"key":"i1543-2165-131-5-719-b8","series-title":"Transfusion","first-page":"32","article-title":"Transmission of syphilis by fresh blood components.","volume":"9","author":"Chambers, R. W.","year":"1969","unstructured":"Chambers, R. W., H. T.Foley, and P. J.Schmidt. Transmission of syphilis by fresh blood components.Transfusion1969. 9:32\u201334."},{"key":"i1543-2165-131-5-719-b9","article-title":"Standards for Blood Banks and Transfusion Services. 23rd ed.","author":"Silva, M. A.","unstructured":"Silva, M. A.\n          \n          ed. Standards for Blood Banks and Transfusion Services. 23rd ed.Bethesda, Md: AABB; 2005:11."},{"key":"i1543-2165-131-5-719-b10","series-title":"Curr Hematol Rep","first-page":"121","article-title":"Improving platelet safety: bacterial contamination of platelets.","volume":"3","author":"Brecher, M. E.","year":"2004","unstructured":"Brecher, M. E. and S. N.Hay. Improving platelet safety: bacterial contamination of platelets.Curr Hematol Rep2004. 3:121\u2013127."},{"key":"i1543-2165-131-5-719-b11","series-title":"Transfusion","first-page":"974","article-title":"Monitoring of apheresis platelet bacterial contamination with an automated liquid culture system: a university experience.","volume":"43","author":"Brecher, M. E.","year":"2003","unstructured":"Brecher, M. E., S. N.Hay, and S. J.Rothenberg. Monitoring of apheresis platelet bacterial contamination with an automated liquid culture system: a university experience.Transfusion2003. 43:974\u2013978."},{"key":"i1543-2165-131-5-719-b12","series-title":"Transfusion","first-page":"1493","article-title":"Transfusion-transmitted bacterial infection in the United States, 1998 through 2000.","volume":"41","author":"Kuehnert, M. J.","year":"2001","unstructured":"Kuehnert, M. J., V. R.Roth, and N. R.Haley. et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000.Transfusion2001. 41:1493\u20131499."},{"key":"i1543-2165-131-5-719-b13","series-title":"Transfusion","first-page":"862","article-title":"BACTHEM Group, French Haemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study.","volume":"41","author":"Perez, P.","year":"2001","unstructured":"Perez, P., L. R.Salmi, and G.Follea. et al. BACTHEM Group, French Haemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study.Transfusion2001. 41:862\u2013871."},{"key":"i1543-2165-131-5-719-b14","article-title":"SHOT report for 2000\u20132001. (Cumulative data 01\/10\/1995\u201330\/09\/2002).","unstructured":"Serious Hazards of Transfusion (SHOT).\n          \n          SHOT report for 2000\u20132001. (Cumulative data 01\/10\/1995\u201330\/09\/2002).\n          Available at: http:\/\/www.shot.demon.co.uk\/toc.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b15","series-title":"Clin Microbiol Rev","first-page":"195","article-title":"Bacterial contamination of blood components.","volume":"18","author":"Brecher, M. E.","year":"2005","unstructured":"Brecher, M. E. and S. N.Hay. Bacterial contamination of blood components.Clin Microbiol Rev2005. 18:195\u2013204."},{"key":"i1543-2165-131-5-719-b16","series-title":"Curr Nanosci","first-page":"189","article-title":"Place of nanofiltration for assuring viral safety of biologicals.","volume":"1","author":"Burnouf, T.","year":"2005","unstructured":"Burnouf, T., M.Radosevich, H. A.Goubran, and A.Willkommen. Place of nanofiltration for assuring viral safety of biologicals.Curr Nanosci2005. 1:189\u2013201."},{"key":"i1543-2165-131-5-719-b17","series-title":"Transfus Med Rev","first-page":"110","article-title":"Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.","volume":"19","author":"Allain, J. P.","year":"2005","unstructured":"Allain, J. P., C.Bianco, and M. A.Blajchman. et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.Transfus Med Rev2005. 19:110\u2013126."},{"key":"i1543-2165-131-5-719-b18","series-title":"Nat Med","first-page":"403","article-title":"Identification of a human population infected with simian foamy viruses.","volume":"4","author":"Heneine, W.","year":"1998","unstructured":"Heneine, W., W. M.Switzer, and P.Sandstrom. et al. Identification of a human population infected with simian foamy viruses.Nat Med1998. 4:403\u2013407."},{"key":"i1543-2165-131-5-719-b19","series-title":"J Virol","first-page":"2780","article-title":"Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates.","volume":"78","author":"Switzer, W. M.","year":"2004","unstructured":"Switzer, W. M., V.Bhullar, and V.Shanmugam. et al. Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates.J Virol2004. 78:2780\u20132789."},{"key":"i1543-2165-131-5-719-b20","series-title":"Curr Opin Hematol","first-page":"405","article-title":"Risk and prevention of transfusion transmitted babesiosis and other tick-borne diseases.","volume":"10","author":"Cable, R. G.","year":"2003","unstructured":"Cable, R. G. and D. A.Leiby. Risk and prevention of transfusion transmitted babesiosis and other tick-borne diseases.Curr Opin Hematol2003. 10:405\u2013411."},{"key":"i1543-2165-131-5-719-b21","series-title":"Lancet","first-page":"417","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.","volume":"363","author":"Llewelyn, C. A.","year":"2004","unstructured":"Llewelyn, C. A., P. E.Hewitt, and R. S. G.Knight. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.Lancet2004. 363:417\u2013421."},{"key":"i1543-2165-131-5-719-b22","series-title":"Lancet","first-page":"527","article-title":"Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.","volume":"264","author":"Peden, A. H.","year":"2004","unstructured":"Peden, A. H., M. W.Head, D. L.Ritchie, J. E.Bell, and J. W.Ironside. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.Lancet2004. 264:527\u2013529."},{"key":"i1543-2165-131-5-719-b23","article-title":"Third vCJD \u201cblood case\u201d diagnosed. BBC News. February 9, 2006.","unstructured":"BBC News.\n          \n          Third vCJD \u201cblood case\u201d diagnosed. BBC News. February 9, 2006.\n          Available at: http:\/\/news.bbc.co.uk\/2\/hi\/health\/4696522.stm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b24","series-title":"Transfusion","first-page":"992","article-title":"Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectives.","volume":"43","author":"Hollinger, F. B.","year":"2003","unstructured":"Hollinger, F. B. and S.Kleinman. Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectives.Transfusion2003. 43:992\u2013997."},{"key":"i1543-2165-131-5-719-b25","series-title":"Lancet","first-page":"261","article-title":"Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey.","volume":"358","author":"Mostashari, F.","year":"2001","unstructured":"Mostashari, F., M. L.Bunning, and P. T.Kitsutani. et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey.Lancet2001. 358:261\u2013264."},{"key":"i1543-2165-131-5-719-b26","series-title":"Transfusion","first-page":"1019","article-title":"Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City.","volume":"42","author":"Biggerstaff, B. J.","year":"2002","unstructured":"Biggerstaff, B. J. and L. R.Petersen. Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City.Transfusion2002. 42:1019\u20131026."},{"key":"i1543-2165-131-5-719-b27","article-title":"Statistics, surveillance, and control. West Nile virus 2003 human cases as of August 12, 2003.","unstructured":"Centers for Disease Control and Prevention.\n          \n          Statistics, surveillance, and control. West Nile virus 2003 human cases as of August 12, 2003.\n          Available at: http:\/\/www.cdc.gov\/ncidod\/dvbid\/westnile\/surv&controlCaseCount03.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b28","article-title":"West Nile Virus Monitor, Human Surveillance (2002\u20132005).","unstructured":"Public Health Agency of Canada.\n          \n          West Nile Virus Monitor, Human Surveillance (2002\u20132005).\n          Available at: http:\/\/www.phac-aspc.gc.ca\/wnv-vwn\/mon-hmnsurv-archive_e.html. Accessed November 27, 2006."},{"key":"i1543-2165-131-5-719-b29","article-title":"Investigations of West Nile virus infections in recipients of blood transfusions.","unstructured":"Centers for Disease Control and Prevention.\n          \n          Investigations of West Nile virus infections in recipients of blood transfusions.\n          Available at: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5139a5.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b30","series-title":"N Engl J Med","first-page":"1236","article-title":"West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002.","volume":"349","author":"Pealer, L. N.","year":"2003","unstructured":"Pealer, L. N., A. A.Marfin, and L. R.Petersen. et al. West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002.N Engl J Med2003. 349:1236\u20131245."},{"key":"i1543-2165-131-5-719-b31","article-title":"Fact sheets. Blood safety and volunteer donations.","unstructured":"World Health Organization.\n          \n          Fact sheets. Blood safety and volunteer donations.\n          Available at: http:\/\/www.wpro.who.int\/media_centre\/fact_sheets\/fs_20040610.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b32","series-title":"Lancet","first-page":"2151","article-title":"Blood supply and demand.","volume":"365","year":"2005","unstructured":"Blood supply and demand.\n          Lancet\n          2005. 365:2151."},{"key":"i1543-2165-131-5-719-b33","series-title":"Transfus Med Rev","first-page":"57","article-title":"Clearance of prions during plasma protein manufacture.","volume":"20","author":"Burdick, M. D.","year":"2006","unstructured":"Burdick, M. D., D. Y.Pifat, S. R. JrPetteway, and K.Cai. Clearance of prions during plasma protein manufacture.Transfus Med Rev2006. 20:57\u201362."},{"key":"i1543-2165-131-5-719-b34","article-title":"Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma.","unstructured":"World Health Organization.\n          \n          Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma.\n          Geneva, Switzerland: World Health Organization; 2004. WHO technical report, Series No. 924."},{"key":"i1543-2165-131-5-719-b35","series-title":"J Intern Med","first-page":"224","article-title":"Pathogen inactivation technology: cleansing the blood supply.","volume":"257","author":"Klein, H. G.","year":"2005","unstructured":"Klein, H. G.\n          \n          Pathogen inactivation technology: cleansing the blood supply.\n          J Intern Med\n          2005. 257:224\u2013237."},{"key":"i1543-2165-131-5-719-b36","series-title":"Transfusion","first-page":"1160","article-title":"The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.","volume":"39","author":"Tabor, E.","year":"1999","unstructured":"Tabor, E.\n          \n          The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.\n          Transfusion\n          1999. 39:1160\u20131168."},{"key":"i1543-2165-131-5-719-b37","series-title":"Biotechnol Appl Biochem","first-page":"141","article-title":"An adventure in biotechnology: the development of haemophilia A therapeutics\u2014from whole blood transfusion to recombinant DNA to gene therapy.","volume":"35","author":"Kingdon, H. S.","year":"2002","unstructured":"Kingdon, H. S. and R. L.Lundblad. An adventure in biotechnology: the development of haemophilia A therapeutics\u2014from whole blood transfusion to recombinant DNA to gene therapy.Biotechnol Appl Biochem2002. 35:141\u2013148."},{"key":"i1543-2165-131-5-719-b38","series-title":"Lancet","first-page":"1013","article-title":"Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform.","volume":"2","author":"Mannucci, P. M.","year":"1985","unstructured":"Mannucci, P. M., M.Colombo, and F.Rodeghiero. Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform.Lancet1985. 2:1013."},{"key":"i1543-2165-131-5-719-b39","series-title":"Ann Intern Med","first-page":"113","article-title":"Heated clotting factors and seroconversion for human immunodeficiency virus in three hemophilic patients.","volume":"107","author":"Mariani, G.","year":"1987","unstructured":"Mariani, G., A.Ghirardini, and F.Mandelli. et al. Heated clotting factors and seroconversion for human immunodeficiency virus in three hemophilic patients.Ann Intern Med1987. 107:113."},{"key":"i1543-2165-131-5-719-b40","series-title":"J Med Virol","first-page":"50","article-title":"Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.","volume":"30","author":"Skidmore, S. J.","year":"1990","unstructured":"Skidmore, S. J., K. J.Pasi, S. J.Mawson, M. D.Williams, and F. G.Hill. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.J Med Virol1990. 30:50\u201352."},{"key":"i1543-2165-131-5-719-b41","series-title":"Am J Hematol","first-page":"228","article-title":"Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.","volume":"39","author":"Azzi, A.","year":"1992","unstructured":"Azzi, A., S.Ciappi, K.Zakvrzewska, M.Morfini, G.Mariani, and P. M.Mannucci. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.Am J Hematol1992. 39:228\u2013230."},{"key":"i1543-2165-131-5-719-b42","series-title":"Am J Hematol","first-page":"142","article-title":"Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment.","volume":"35","author":"Rubinstein, A. I.","year":"1990","unstructured":"Rubinstein, A. I. and D. B.Rubinstein. Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment.Am J Hematol1990. 35:142."},{"key":"i1543-2165-131-5-719-b43","series-title":"Biologicals","first-page":"115","article-title":"Assessment of the viral safety of antivenoms fractionated from equine plasma.","volume":"32","author":"Burnouf, T.","year":"2004","unstructured":"Burnouf, T., E.Griffiths, A.Padilla, S.Seddik, M. A.Stephano, and J. M.Gutierrez. Assessment of the viral safety of antivenoms fractionated from equine plasma.Biologicals2004. 32:115\u2013128."},{"key":"i1543-2165-131-5-719-b44","series-title":"Transfus Clin Biol","first-page":"167","article-title":"Viral safety of intravenous immunoglobulins G for therapeutic use.","volume":"2","author":"Burnouf-Radosevich, M.","year":"1995","unstructured":"Burnouf-Radosevich, M.\n          \n          Viral safety of intravenous immunoglobulins G for therapeutic use.\n          Transfus Clin Biol\n          1995. 2:167\u2013179."},{"key":"i1543-2165-131-5-719-b45","series-title":"Transfusion","first-page":"866","article-title":"Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation.","volume":"36","author":"Omar, A.","year":"1996","unstructured":"Omar, A., C.Kempf, A.Immelmann, M.Rentsch, and J. J.Morgenthaler. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation.Transfusion1996. 36:866\u2013872."},{"key":"i1543-2165-131-5-719-b46","series-title":"Biologicals","first-page":"267","article-title":"Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.","volume":"26","author":"Bos, O. J.","year":"1998","unstructured":"Bos, O. J., D. G.Sunye, C. E.Nieuweboer, F. A.van Engelenburg, H.Schuitemaker, and J.Over. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.Biologicals1998. 26:267\u2013276."},{"key":"i1543-2165-131-5-719-b47","series-title":"Vox Sang","first-page":"75","article-title":"Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.","volume":"55","author":"Reid, K. G.","year":"1988","unstructured":"Reid, K. G., B.Cuthbertson, A. D.Jones, and R. V.McIntosh. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.Vox Sang1988. 55:75\u201380."},{"key":"i1543-2165-131-5-719-b48","series-title":"Lancet","first-page":"706","article-title":"Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.","volume":"1","author":"Prince, A. M.","year":"1986","unstructured":"Prince, A. M., B.Horowitz, and B.Brotman. Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.Lancet1986. 1:706\u2013710."},{"key":"i1543-2165-131-5-719-b49","series-title":"Transfusion","first-page":"102","article-title":"Current status of solvent\/detergent-treated frozen plasma.","volume":"38","author":"Klein, H. G.","year":"1998","unstructured":"Klein, H. G., R. Y.Dodd, and W. H.Dzik. et al. Current status of solvent\/detergent-treated frozen plasma.Transfusion1998. 38:102\u2013107."},{"key":"i1543-2165-131-5-719-b50","series-title":"Br J Haematol","first-page":"778","article-title":"Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura.","volume":"121","author":"Yarranton, H.","year":"2003","unstructured":"Yarranton, H., H.Cohen, S. R.Pavord, S.Benjamin, D.Hagger, and S. J.Machin. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura.Br J Haematol2003. 121:778\u2013785."},{"key":"i1543-2165-131-5-719-b51","series-title":"Transfusion","first-page":"1227","article-title":"A randomized trial of solvent\/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.","volume":"39","author":"Williamson, L. M.","year":"1999","unstructured":"Williamson, L. M., C. A.Llewelyn, and N. C.Fisher. et al. A randomized trial of solvent\/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.Transfusion1999. 39:1227\u20131234."},{"key":"i1543-2165-131-5-719-b52","series-title":"Transfusion","first-page":"2100","article-title":"A process for solvent\/detergent treatment of plasma for transfusion at blood centers using a disposable-bag system.","volume":"46","author":"Burnouf, T.","year":"2006","unstructured":"Burnouf, T., H. A.Goubran, M.Radosevich, M. A.Sayed, G.Gorgy, and M.El-Ekiaby. A process for solvent\/detergent treatment of plasma for transfusion at blood centers using a disposable-bag system.Transfusion2006. 46:2100\u20132108."},{"key":"i1543-2165-131-5-719-b53","series-title":"Haemophilia","first-page":"24","article-title":"Nanofiltration of plasma-derived biopharmaceutical products.","volume":"9","author":"Burnouf, T.","year":"2003","unstructured":"Burnouf, T. and M.Radosevich. Nanofiltration of plasma-derived biopharmaceutical products.Haemophilia2003. 9:24\u201337."},{"key":"i1543-2165-131-5-719-b54","series-title":"Vox Sang","first-page":"225","article-title":"Removal of small non-enveloped viruses by nanofiltration.","volume":"86","author":"Yokoyama, T.","year":"2004","unstructured":"Yokoyama, T., K.Murai, and T.Murozuka. et al. Removal of small non-enveloped viruses by nanofiltration.Vox Sang2004. 86:225\u2013229."},{"key":"i1543-2165-131-5-719-b55","series-title":"Transfus Med Rev","first-page":"61","article-title":"Virus inactivation in blood components by photoactive phenothiazine dyes.","volume":"16","author":"Wagner, S. J.","year":"2002","unstructured":"Wagner, S. J.\n          \n          Virus inactivation in blood components by photoactive phenothiazine dyes.\n          Transfus Med Rev\n          2002. 16:61\u201366."},{"key":"i1543-2165-131-5-719-b56","series-title":"Immunol Invest","first-page":"73","article-title":"Photodynamic virus inactivation of blood components.","volume":"24","author":"Mohr, H.","year":"1995","unstructured":"Mohr, H., B.Lambrecht, and A.Selz. Photodynamic virus inactivation of blood components.Immunol Invest1995. 24:73\u201385."},{"key":"i1543-2165-131-5-719-b57","series-title":"Transfusion","first-page":"1322","article-title":"Methylene blue treated fresh-frozen plasma: what is its contribution to blood safety?","volume":"43","author":"Williamson, L. M.","year":"2003","unstructured":"Williamson, L. M., R.Cardigan, and C. V.Prowse. Methylene blue treated fresh-frozen plasma: what is its contribution to blood safety?Transfusion2003. 43:1322\u20131329."},{"key":"i1543-2165-131-5-719-b58","series-title":"Transfus Apher Sci","first-page":"183","article-title":"Methylene blue and thionine in pathogen inactivation of plasma and platelet concentrates.","volume":"25","author":"Mohr, H.","year":"2001","unstructured":"Mohr, H.\n          \n          Methylene blue and thionine in pathogen inactivation of plasma and platelet concentrates.\n          Transfus Apher Sci\n          2001. 25:183\u2013184."},{"key":"i1543-2165-131-5-719-b59","series-title":"Blood Cells","first-page":"7","article-title":"Photochemical inactivation of viruses with psoralens: an overview.","volume":"18","author":"Hanson, C. V.","year":"1992","unstructured":"Hanson, C. V.\n          \n          Photochemical inactivation of viruses with psoralens: an overview.\n          Blood Cells\n          1992. 18:7\u201325."},{"key":"i1543-2165-131-5-719-b60","series-title":"Transfusion","first-page":"423","article-title":"Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.","volume":"37","author":"Lin, L.","year":"1997","unstructured":"Lin, L., D. N.Cook, and G. P.Wiesehahn. et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.Transfusion1997. 37:423\u2013435."},{"key":"i1543-2165-131-5-719-b61","series-title":"Blood Cells","first-page":"57","article-title":"Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates.","volume":"18","author":"Corash, L.","year":"1992","unstructured":"Corash, L., L.Lin, and G.Wiesehahn. Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates.Blood Cells1992. 18:57\u201373."},{"key":"i1543-2165-131-5-719-b62","series-title":"Blood Cells","first-page":"43","article-title":"Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet A light.","volume":"18","author":"Moroff, G.","year":"1992","unstructured":"Moroff, G., S.Wagner, L.Benade, and R. Y.Dodd. Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet A light.Blood Cells1992. 18:43\u201354."},{"key":"i1543-2165-131-5-719-b63","series-title":"Vox Sang","first-page":"206","article-title":"Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats.","volume":"79","author":"van Rhenen, D. J.","year":"2000","unstructured":"van Rhenen, D. J., J.Vermeij, V.Mayaudon, C.Hind, L.Lin, and L.Corash. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats.Vox Sang2000. 79:206\u2013214."},{"key":"i1543-2165-131-5-719-b64","series-title":"Hum Exp Toxicol","first-page":"533","article-title":"Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets.","volume":"20","author":"Ciaravino, V.","year":"2001","unstructured":"Ciaravino, V., T.McCullough, and A. D.Dayan. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets.Hum Exp Toxicol2001. 20:533\u2013550."},{"key":"i1543-2165-131-5-719-b65","series-title":"Blood","first-page":"1534","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.","volume":"104","author":"McCullough, J.","year":"2004","unstructured":"McCullough, J., D. H.Vesole, and R. J.Benjamin. et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.Blood2004. 104:1534\u20131541."},{"key":"i1543-2165-131-5-719-b66","series-title":"Transfusion","first-page":"1443","article-title":"Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.","volume":"45","author":"Janetzko, K.","year":"2005","unstructured":"Janetzko, K., J. P.Cazenave, and H.Kluter. et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.Transfusion2005. 45:1443\u20131452."},{"key":"i1543-2165-131-5-719-b67","series-title":"Transfusion","first-page":"1864","article-title":"Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.","volume":"45","author":"Snyder, E.","year":"2005","unstructured":"Snyder, E., J.McCullough, and S. J.Slichter. et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.Transfusion2005. 45:1864\u20131875."},{"key":"i1543-2165-131-5-719-b68","series-title":"Transfusion","first-page":"24","article-title":"Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.","volume":"46","author":"Murphy, S.","year":"2006","unstructured":"Murphy, S., E.Snyder, and R.Cable. et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.Transfusion2006. 46:24\u201333."},{"key":"i1543-2165-131-5-719-b69","series-title":"Vox Sang","first-page":"171","article-title":"Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.","volume":"85","author":"Ciaravino, V.","year":"2003","unstructured":"Ciaravino, V., T.McCullough, G.Cimino, and T.Sullivan. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.Vox Sang2003. 85:171\u2013182."},{"key":"i1543-2165-131-5-719-b70","series-title":"Transfusion","first-page":"1168","article-title":"Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.","volume":"46","author":"Sing, Y.","year":"2006","unstructured":"Sing, Y., L. S.Sawyer, and L. S.Pinkoski. et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.Transfusion2006. 46:1168\u20131177."},{"key":"i1543-2165-131-5-719-b71","series-title":"Transfusion","first-page":"1302","article-title":"Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin.","volume":"42","author":"Hambleton, J.","year":"2002","unstructured":"Hambleton, J., D.Wages, and L.Radu-Radulescu. et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin.Transfusion2002. 42:1302\u20131307."},{"key":"i1543-2165-131-5-719-b72","series-title":"Transfusion","first-page":"1362","article-title":"Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.","volume":"45","author":"de Alarcon, P.","year":"2005","unstructured":"de Alarcon, P., R.Benjamin, and M.Dugdale. et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.Transfusion2005. 45:1362\u20131372."},{"key":"i1543-2165-131-5-719-b73","series-title":"Blood","first-page":"3753","article-title":"Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.","volume":"107","author":"Mintz, P. D.","year":"2006","unstructured":"Mintz, P. D., N. M.Bass, and L. D.Petz. et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.Blood2006. 107:3753\u20133760."},{"key":"i1543-2165-131-5-719-b74","series-title":"Transfusion","first-page":"30A","article-title":"vWF cleaving protease activity and inhibitors in patients with thrombotic thrombocytopenic purpura (TTP) treated with INTERCEPT FFP vs. conventional FFP: results of a phase III trial.","volume":"45","author":"Conlan, M. G.","year":"2005","unstructured":"Conlan, M. G., L.Corash, and J.Lin. et al. vWF cleaving protease activity and inhibitors in patients with thrombotic thrombocytopenic purpura (TTP) treated with INTERCEPT FFP vs. conventional FFP: results of a phase III trial.Transfusion2005. 45:30A."},{"key":"i1543-2165-131-5-719-b75","series-title":"Transfusion","first-page":"1693","article-title":"A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.","volume":"46","author":"Mintz, P. D.","year":"2006","unstructured":"Mintz, P. D., A.Neff, and M.MacKenzie. et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.Transfusion2006. 46:1693\u20131704."},{"key":"i1543-2165-131-5-719-b76","series-title":"Transfusion","first-page":"63s","article-title":"Preparation of cryoprecipitate from photochemically treated fresh frozen plasma.","volume":"40","author":"Mintz, P. D.","year":"2000","unstructured":"Mintz, P. D., N. L.Avery, and S. L.Monlaison. et al. Preparation of cryoprecipitate from photochemically treated fresh frozen plasma.Transfusion2000. 40:63s."},{"key":"i1543-2165-131-5-719-b77","series-title":"Transfusion","first-page":"1453","article-title":"Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.","volume":"45","author":"Yarranton, H.","year":"2005","unstructured":"Yarranton, H., A. S.Lawrie, I. J.Mackie, L.Pinkoski, L.Corash, and S. J.Machin. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.Transfusion2005. 45:1453\u20131458."},{"key":"i1543-2165-131-5-719-b78","series-title":"Photochem Photobiol","first-page":"561","article-title":"Binding affinities of commonly employed sensitizers of viral inactivation.","volume":"75","author":"Dardare, N.","year":"2002","unstructured":"Dardare, N. and M. S.Platz. Binding affinities of commonly employed sensitizers of viral inactivation.Photochem Photobiol2002. 75:561\u2013564."},{"key":"i1543-2165-131-5-719-b79","series-title":"Photochem Photobiol","first-page":"609","article-title":"Separation, identification and quantification of riboflavin and its photoproducts in blood products using HPLC with fluorescence detection: a method to support pathogen reduction technology.","volume":"80","author":"Hardwick, C. C.","year":"2004","unstructured":"Hardwick, C. C., T. R.Herivel, S. C.Hernandez, P. H.Ruane, and R. P.Goodrich. Separation, identification and quantification of riboflavin and its photoproducts in blood products using HPLC with fluorescence detection: a method to support pathogen reduction technology.Photochem Photobiol2004. 80:609\u2013615."},{"key":"i1543-2165-131-5-719-b80","article-title":"Vitamin B,.","unstructured":"US Food and Drug Administration.\n          \n          Vitamin B,.\n          21 CFR 582.5695 (1998)."},{"key":"i1543-2165-131-5-719-b81","series-title":"Transfusion","first-page":"877","article-title":"Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.","volume":"44","author":"Ruane, P. H.","year":"2004","unstructured":"Ruane, P. H., R.Edrich, D.Gampp, S. D.Keil, R. L.Leonard, and R. P.Goodrich. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.Transfusion2004. 44:877\u2013885."},{"key":"i1543-2165-131-5-719-b82","series-title":"Vox Sang","first-page":"211","article-title":"The use of riboflavin for the inactivation of pathogens in blood products.","volume":"78","author":"Goodrich, R. P.","year":"2000","unstructured":"Goodrich, R. P.\n          \n          The use of riboflavin for the inactivation of pathogens in blood products.\n          Vox Sang\n          2000. 78:(S2). 211\u2013215."},{"key":"i1543-2165-131-5-719-b83","series-title":"Transfus Apher Sci","first-page":"189","article-title":"Use of riboflavin for photoinactivation of pathogens in blood components.","volume":"25","author":"Schuyler, R.","year":"2001","unstructured":"Schuyler, R.\n          \n          Use of riboflavin for photoinactivation of pathogens in blood components.\n          Transfus Apher Sci\n          2001. 25:189\u2013190."},{"key":"i1543-2165-131-5-719-b84","series-title":"Vox Sang","first-page":"85","article-title":"Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.","volume":"90","author":"Cardo, L. J.","year":"2006","unstructured":"Cardo, L. J., F. J.Rentas, and L.Ketchum. et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.Vox Sang2006. 90:85\u201391."},{"key":"i1543-2165-131-5-719-b85","series-title":"Transfusion","first-page":"1750","article-title":"Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage.","volume":"45","author":"Li, J.","year":"2005","unstructured":"Li, J., L.Goodrich, E.Hansen, R.Edrich, D.Gampp, and R. P.Goodrich. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage.Transfusion2005. 45:1750\u20131758."},{"key":"i1543-2165-131-5-719-b86","series-title":"Vox Sang","first-page":"183s","article-title":"Mirasol pathogen reduction treated fresh frozen plasma maintains protein quality.","volume":"91","author":"Buytaert-Hoefen, K. A.","year":"2006","unstructured":"Buytaert-Hoefen, K. A., D.Gampp, R.Edrich, and R.Goodrich. Mirasol pathogen reduction treated fresh frozen plasma maintains protein quality.Vox Sang2006. 91:183s."},{"key":"i1543-2165-131-5-719-b87","series-title":"Transfus Apher Sci","first-page":"179","article-title":"Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.","volume":"25","author":"Corash, L.","year":"2001","unstructured":"Corash, L.\n          \n          Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.\n          Transfus Apher Sci\n          2001. 25:179\u2013181."},{"key":"i1543-2165-131-5-719-b88","series-title":"Transfus Clin Biol","first-page":"138","article-title":"Inactivation of infectious pathogens in labile blood components: meeting the challenge.","volume":"8","author":"Corash, L.","year":"2001","unstructured":"Corash, L.\n          \n          Inactivation of infectious pathogens in labile blood components: meeting the challenge.\n          Transfus Clin Biol\n          2001. 8:138\u2013145."},{"key":"i1543-2165-131-5-719-b89","series-title":"Transfusion","first-page":"1739","article-title":"Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients.","volume":"45","author":"Benjamin, R. J.","year":"2005","unstructured":"Benjamin, R. J., J.McCullough, and P. D.Mintz. et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients.Transfusion2005. 45:1739\u20131749."},{"key":"i1543-2165-131-5-719-b90","series-title":"Blood","first-page":"130a","article-title":"Antibodies to S-303 treated red blood cells prepared with the original treatment process for pathogen inactivation do not react with red blood cells prepared with a modified S-303 treatment process.","volume":"106","author":"Conlan, M. G.","year":"2005","unstructured":"Conlan, M. G., G.Garrity, and G.Castro. et al. Antibodies to S-303 treated red blood cells prepared with the original treatment process for pathogen inactivation do not react with red blood cells prepared with a modified S-303 treatment process.Blood2005. 106:130a."},{"key":"i1543-2165-131-5-719-b91","series-title":"Transfusion","first-page":"1308","article-title":"Inactivation of HIV in blood.","volume":"42","author":"Ohagen, A.","year":"2002","unstructured":"Ohagen, A., V.Gibaja, S.Aytay, J.Horrigan, D.Lunderfille, and A.Lazo. Inactivation of HIV in blood.Transfusion2002. 42:1308\u20131317."},{"key":"i1543-2165-131-5-719-b92","series-title":"Transfusion","first-page":"1029","article-title":"West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation.","volume":"43","author":"Mather, T.","year":"2003","unstructured":"Mather, T., T.Takeda, and J.Tassello. et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation.Transfusion2003. 43:1029\u20131037."},{"key":"i1543-2165-131-5-719-b93","series-title":"Transfusion","first-page":"139","article-title":"Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies.","volume":"42","author":"Purmal, A.","year":"2002","unstructured":"Purmal, A., C. R.Valeri, and W.Dzik. et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies.Transfusion2002. 42:139\u2013145."},{"key":"i1543-2165-131-5-719-b94","series-title":"Vox Sang","first-page":"313","article-title":"Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry.","volume":"83","author":"Lazo, A.","year":"2002","unstructured":"Lazo, A., J.Tassello, and V.Jayarama. et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry.Vox Sang2002. 83:313\u2013323."},{"key":"i1543-2165-131-5-719-b95","series-title":"Vox Sang","first-page":"1","article-title":"Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.","volume":"87","author":"Ohagen, A.","year":"2004","unstructured":"Ohagen, A., V.Gibaja, and J.Horrigan. et al. Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.Vox Sang2004. 87:1\u20139."},{"key":"i1543-2165-131-5-719-b96","series-title":"Transfusion","first-page":"731","article-title":"Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry.","volume":"44","author":"Zavizion, B.","year":"2004","unstructured":"Zavizion, B., M.Pereira, and J. M.de Melo. et al. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry.Transfusion2004. 44:731\u2013738."},{"key":"i1543-2165-131-5-719-b97","series-title":"Transfusion","first-page":"286","article-title":"Inactivation of mycoplasma species in blood by INACTINE PEN110 process.","volume":"44","author":"Zavizion, B.","year":"2004","unstructured":"Zavizion, B., A.Purmal, J.Chapman, and B.Alford. Inactivation of mycoplasma species in blood by INACTINE PEN110 process.Transfusion2004. 44:286\u2013293."},{"key":"i1543-2165-131-5-719-b98","series-title":"Transfusion","first-page":"135","article-title":"Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.","volume":"43","author":"Zavizion, B.","year":"2003","unstructured":"Zavizion, B., D.Serebryanik, I.Serebryanik, J.Chapman, and A.Purmal. Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.Transfusion2003. 43:135\u2013142."},{"key":"i1543-2165-131-5-719-b99","series-title":"Transfusion","first-page":"146","article-title":"Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a phase I clinical study.","volume":"42","author":"AuBuchon, J. P.","year":"2002","unstructured":"AuBuchon, J. P., C. A.Pickard, and L. H.Herschel. et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a phase I clinical study.Transfusion2002. 42:146\u2013152."},{"key":"i1543-2165-131-5-719-b100","series-title":"Transfus Med Rev","first-page":"61","article-title":"Virus inactivation in blood components by photoactive phenothiazine dyes.","volume":"16","author":"Wagner, S. J.","year":"2002","unstructured":"Wagner, S. J.\n          \n          Virus inactivation in blood components by photoactive phenothiazine dyes.\n          Transfus Med Rev\n          2002. 16:61\u201366."},{"key":"i1543-2165-131-5-719-b101","series-title":"Dev Biol Stand","first-page":"125","article-title":"The use of dimethylmethylene blue for virus photoinactivation of red cell suspensions.","volume":"102","author":"Wagner, S. J.","year":"2000","unstructured":"Wagner, S. J., A.Skripchenko, and D.Robinette. et al. The use of dimethylmethylene blue for virus photoinactivation of red cell suspensions.Dev Biol Stand2000. 102:125\u2013129."},{"key":"i1543-2165-131-5-719-b102","series-title":"Transfusion","first-page":"968","article-title":"Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB.","volume":"40","author":"Skripchenko, A. A.","year":"2000","unstructured":"Skripchenko, A. A. and S. J.Wagner. Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB.Transfusion2000. 40:968\u2013975."},{"key":"i1543-2165-131-5-719-b103","series-title":"Transfusion","first-page":"729","article-title":"Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue.","volume":"38","author":"Wagner, S. J.","year":"1998","unstructured":"Wagner, S. J., A.Skripchenko, D.Robinette, D. A.Mallory, and L.Cincotta. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue.Transfusion1998. 38:729\u2013737."},{"key":"i1543-2165-131-5-719-b104","series-title":"Vox Sang","first-page":"183","article-title":"Composition of the additive solution affects red blood cell integrity after photodynamic treatment.","volume":"85","author":"Besselink, G. A. J.","year":"2003","unstructured":"Besselink, G. A. J., I. G.Ebbing, P. M.Hilarius, D.de Korte, A. J.Verhoeven, and J. W. M.Lagerberg. Composition of the additive solution affects red blood cell integrity after photodynamic treatment.Vox Sang2003. 85:183\u2013189."},{"key":"i1543-2165-131-5-719-b105","series-title":"Transfusion","first-page":"752","article-title":"Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties.","volume":"45","author":"Wagner, S. J.","year":"2005","unstructured":"Wagner, S. J., A.Skripchenko, L.Cincotta, D.Thompson-Montgomery, and H.Awatefe. Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties.Transfusion2005. 45:752\u2013760."},{"key":"i1543-2165-131-5-719-b106","series-title":"Transfusion","first-page":"213","article-title":"Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties.","volume":"46","author":"Skripchenko, A.","year":"2006","unstructured":"Skripchenko, A., S. J.Wagner, D.Thompson-Montgomery, and H.Awatefe. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties.Transfusion2006. 46:213\u2013219."},{"key":"i1543-2165-131-5-719-b107","series-title":"Lancet","first-page":"529","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood.","volume":"364","author":"Gregori, L.","year":"2004","unstructured":"Gregori, L., N.McCombie, and D.Palmer. et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood.Lancet2004. 364:529\u2013531."},{"key":"i1543-2165-131-5-719-b108","series-title":"Transfusion","first-page":"1839","article-title":"Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.","volume":"45","author":"Sowemimo-Coker, S.","year":"2005","unstructured":"Sowemimo-Coker, S., R.Kascsak, and A.Kim. et al. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.Transfusion2005. 45:1839\u20131844."},{"key":"i1543-2165-131-5-719-b109","series-title":"Semin Hematol","first-page":"27","article-title":"Inactivation of cytomegalovirus in platelet concentrates using Helinx technology.","volume":"38","author":"Lin, L.","year":"2001","unstructured":"Lin, L.\n          \n          Inactivation of cytomegalovirus in platelet concentrates using Helinx technology.\n          Semin Hematol\n          2001. 38:(4S11). 27\u201333."},{"key":"i1543-2165-131-5-719-b110","series-title":"Transfusion","first-page":"1496","article-title":"Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.","volume":"44","author":"Lin, L.","year":"2004","unstructured":"Lin, L., R.Dikeman, and B.Molini. et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.Transfusion2004. 44:1496\u20131504."},{"key":"i1543-2165-131-5-719-b111","series-title":"Vox Sang","first-page":"209","article-title":"Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function.","volume":"78","author":"Knutson, F.","year":"2000","unstructured":"Knutson, F., R.Alfonso, and K.Dupuis. et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function.Vox Sang2000. 78:209\u2013216."},{"key":"i1543-2165-131-5-719-b112","series-title":"Transfus Med Rev","first-page":"45","article-title":"The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.","volume":"20","author":"Roback, J. D.","year":"2006","unstructured":"Roback, J. D., M.Conlan, W. L.Drew, P.Ljungman, W. G.Nichols, and J. K.Preiksaitis. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.Transfus Med Rev2006. 20:45\u201356."},{"key":"i1543-2165-131-5-719-b113","series-title":"Transfusion","first-page":"1459","article-title":"Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.","volume":"45","author":"Eastman, R. T.","year":"2005","unstructured":"Eastman, R. T., L. K.Barrett, K.Dupuis, F. S.Buckner, and W. C.Van Voorhis. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.Transfusion2005. 45:1459\u20131463."},{"key":"i1543-2165-131-5-719-b1","series-title":"JAMA","first-page":"1332","article-title":"Jaundice occurring one to four months after transfusion of blood or plasma\u2014report of seven cases.","volume":"121","author":"Beeson, P. B.","year":"1943","unstructured":"Beeson, P. B.\n          \n          Jaundice occurring one to four months after transfusion of blood or plasma\u2014report of seven cases.\n          JAMA\n          1943. 121:1332\u20131334."},{"key":"i1543-2165-131-5-719-b2","series-title":"Transfusion","first-page":"975","article-title":"Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood door population.","volume":"42","author":"Dodd, R. Y.","year":"2002","unstructured":"Dodd, R. Y., E. P.Notari, and S. L.Stramer. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood door population.Transfusion2002. 42:975\u2013979."},{"key":"i1543-2165-131-5-719-b3","series-title":"Ann Intern Med","first-page":"537","article-title":"Meeting transfusion safety expectations.","volume":"143","author":"AuBuchon, J. P.","year":"2005","unstructured":"AuBuchon, J. P.\n          \n          Meeting transfusion safety expectations.\n          Ann Intern Med\n          2005. 143:537\u2013538."},{"key":"i1543-2165-131-5-719-b4","series-title":"N Engl J Med","first-page":"438","article-title":"Transfusion medicine: first of two parts\u2014blood transfusion.","volume":"340","author":"Goodnough, L. T.","year":"1999","unstructured":"Goodnough, L. T., M. E.Brecher, M. H.Kanter, and J. P.AuBuchon. Transfusion medicine: first of two parts\u2014blood transfusion.N Engl J Med1999. 340:438\u2013447."},{"key":"i1543-2165-131-5-719-b5","series-title":"Haema","first-page":"24","article-title":"Transfusion-transmitted infections: epidemiology, risks and prevention.","volume":"4","author":"Theodossiades, G.","year":"2001","unstructured":"Theodossiades, G. and M.Makris. Transfusion-transmitted infections: epidemiology, risks and prevention.Haema2001. 4:24\u201338."},{"key":"i1543-2165-131-5-719-b6","series-title":"Transfus Clin Biol","first-page":"81","article-title":"Trends in residual risk of transfusion transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (nucleic acid testing).","volume":"11","author":"Pillonel, J.","year":"2004","unstructured":"Pillonel, J. and S.Laperche. Trends in residual risk of transfusion transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (nucleic acid testing).Transfus Clin Biol2004. 11:81\u201386."},{"key":"i1543-2165-131-5-719-b7","series-title":"MMWR Weekly","first-page":"281","article-title":"Update: West Nile virus screening of blood donations and transfusion-associated transmission\u2014United States, 2003.","volume":"53","year":"April 9, 2004","unstructured":"Centers for Disease Control and Prevention.\n          \n          Update: West Nile virus screening of blood donations and transfusion-associated transmission\u2014United States, 2003.\n          MMWR Weekly\n          April 9, 2004. 53:281\u2013284."},{"key":"i1543-2165-131-5-719-b8","series-title":"Transfusion","first-page":"32","article-title":"Transmission of syphilis by fresh blood components.","volume":"9","author":"Chambers, R. W.","year":"1969","unstructured":"Chambers, R. W., H. T.Foley, and P. J.Schmidt. Transmission of syphilis by fresh blood components.Transfusion1969. 9:32\u201334."},{"key":"i1543-2165-131-5-719-b9","article-title":"Standards for Blood Banks and Transfusion Services. 23rd ed.","author":"Silva, M. A.","unstructured":"Silva, M. A.\n          \n          ed. Standards for Blood Banks and Transfusion Services. 23rd ed.Bethesda, Md: AABB; 2005:11."},{"key":"i1543-2165-131-5-719-b10","series-title":"Curr Hematol Rep","first-page":"121","article-title":"Improving platelet safety: bacterial contamination of platelets.","volume":"3","author":"Brecher, M. E.","year":"2004","unstructured":"Brecher, M. E. and S. N.Hay. Improving platelet safety: bacterial contamination of platelets.Curr Hematol Rep2004. 3:121\u2013127."},{"key":"i1543-2165-131-5-719-b11","series-title":"Transfusion","first-page":"974","article-title":"Monitoring of apheresis platelet bacterial contamination with an automated liquid culture system: a university experience.","volume":"43","author":"Brecher, M. E.","year":"2003","unstructured":"Brecher, M. E., S. N.Hay, and S. J.Rothenberg. Monitoring of apheresis platelet bacterial contamination with an automated liquid culture system: a university experience.Transfusion2003. 43:974\u2013978."},{"key":"i1543-2165-131-5-719-b12","series-title":"Transfusion","first-page":"1493","article-title":"Transfusion-transmitted bacterial infection in the United States, 1998 through 2000.","volume":"41","author":"Kuehnert, M. J.","year":"2001","unstructured":"Kuehnert, M. J., V. R.Roth, and N. R.Haley. et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000.Transfusion2001. 41:1493\u20131499."},{"key":"i1543-2165-131-5-719-b13","series-title":"Transfusion","first-page":"862","article-title":"BACTHEM Group, French Haemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study.","volume":"41","author":"Perez, P.","year":"2001","unstructured":"Perez, P., L. R.Salmi, and G.Follea. et al. BACTHEM Group, French Haemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study.Transfusion2001. 41:862\u2013871."},{"key":"i1543-2165-131-5-719-b14","article-title":"SHOT report for 2000\u20132001. (Cumulative data 01\/10\/1995\u201330\/09\/2002).","unstructured":"Serious Hazards of Transfusion (SHOT).\n          \n          SHOT report for 2000\u20132001. (Cumulative data 01\/10\/1995\u201330\/09\/2002).\n          Available at: http:\/\/www.shot.demon.co.uk\/toc.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b15","series-title":"Clin Microbiol Rev","first-page":"195","article-title":"Bacterial contamination of blood components.","volume":"18","author":"Brecher, M. E.","year":"2005","unstructured":"Brecher, M. E. and S. N.Hay. Bacterial contamination of blood components.Clin Microbiol Rev2005. 18:195\u2013204."},{"key":"i1543-2165-131-5-719-b16","series-title":"Curr Nanosci","first-page":"189","article-title":"Place of nanofiltration for assuring viral safety of biologicals.","volume":"1","author":"Burnouf, T.","year":"2005","unstructured":"Burnouf, T., M.Radosevich, H. A.Goubran, and A.Willkommen. Place of nanofiltration for assuring viral safety of biologicals.Curr Nanosci2005. 1:189\u2013201."},{"key":"i1543-2165-131-5-719-b17","series-title":"Transfus Med Rev","first-page":"110","article-title":"Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.","volume":"19","author":"Allain, J. P.","year":"2005","unstructured":"Allain, J. P., C.Bianco, and M. A.Blajchman. et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.Transfus Med Rev2005. 19:110\u2013126."},{"key":"i1543-2165-131-5-719-b18","series-title":"Nat Med","first-page":"403","article-title":"Identification of a human population infected with simian foamy viruses.","volume":"4","author":"Heneine, W.","year":"1998","unstructured":"Heneine, W., W. M.Switzer, and P.Sandstrom. et al. Identification of a human population infected with simian foamy viruses.Nat Med1998. 4:403\u2013407."},{"key":"i1543-2165-131-5-719-b19","series-title":"J Virol","first-page":"2780","article-title":"Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates.","volume":"78","author":"Switzer, W. M.","year":"2004","unstructured":"Switzer, W. M., V.Bhullar, and V.Shanmugam. et al. Frequent simian foamy virus infection in persons occupationally exposed to nonhuman primates.J Virol2004. 78:2780\u20132789."},{"key":"i1543-2165-131-5-719-b20","series-title":"Curr Opin Hematol","first-page":"405","article-title":"Risk and prevention of transfusion transmitted babesiosis and other tick-borne diseases.","volume":"10","author":"Cable, R. G.","year":"2003","unstructured":"Cable, R. G. and D. A.Leiby. Risk and prevention of transfusion transmitted babesiosis and other tick-borne diseases.Curr Opin Hematol2003. 10:405\u2013411."},{"key":"i1543-2165-131-5-719-b21","series-title":"Lancet","first-page":"417","article-title":"Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.","volume":"363","author":"Llewelyn, C. A.","year":"2004","unstructured":"Llewelyn, C. A., P. E.Hewitt, and R. S. G.Knight. et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.Lancet2004. 363:417\u2013421."},{"key":"i1543-2165-131-5-719-b22","series-title":"Lancet","first-page":"527","article-title":"Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.","volume":"264","author":"Peden, A. H.","year":"2004","unstructured":"Peden, A. H., M. W.Head, D. L.Ritchie, J. E.Bell, and J. W.Ironside. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.Lancet2004. 264:527\u2013529."},{"key":"i1543-2165-131-5-719-b23","article-title":"Third vCJD \u201cblood case\u201d diagnosed. BBC News. February 9, 2006.","unstructured":"BBC News.\n          \n          Third vCJD \u201cblood case\u201d diagnosed. BBC News. February 9, 2006.\n          Available at: http:\/\/news.bbc.co.uk\/2\/hi\/health\/4696522.stm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b24","series-title":"Transfusion","first-page":"992","article-title":"Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectives.","volume":"43","author":"Hollinger, F. B.","year":"2003","unstructured":"Hollinger, F. B. and S.Kleinman. Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectives.Transfusion2003. 43:992\u2013997."},{"key":"i1543-2165-131-5-719-b25","series-title":"Lancet","first-page":"261","article-title":"Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey.","volume":"358","author":"Mostashari, F.","year":"2001","unstructured":"Mostashari, F., M. L.Bunning, and P. T.Kitsutani. et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey.Lancet2001. 358:261\u2013264."},{"key":"i1543-2165-131-5-719-b26","series-title":"Transfusion","first-page":"1019","article-title":"Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City.","volume":"42","author":"Biggerstaff, B. J.","year":"2002","unstructured":"Biggerstaff, B. J. and L. R.Petersen. Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City.Transfusion2002. 42:1019\u20131026."},{"key":"i1543-2165-131-5-719-b27","article-title":"Statistics, surveillance, and control. West Nile virus 2003 human cases as of August 12, 2003.","unstructured":"Centers for Disease Control and Prevention.\n          \n          Statistics, surveillance, and control. West Nile virus 2003 human cases as of August 12, 2003.\n          Available at: http:\/\/www.cdc.gov\/ncidod\/dvbid\/westnile\/surv&controlCaseCount03.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b28","article-title":"West Nile Virus Monitor, Human Surveillance (2002\u20132005).","unstructured":"Public Health Agency of Canada.\n          \n          West Nile Virus Monitor, Human Surveillance (2002\u20132005).\n          Available at: http:\/\/www.phac-aspc.gc.ca\/wnv-vwn\/mon-hmnsurv-archive_e.html. Accessed November 27, 2006."},{"key":"i1543-2165-131-5-719-b29","article-title":"Investigations of West Nile virus infections in recipients of blood transfusions.","unstructured":"Centers for Disease Control and Prevention.\n          \n          Investigations of West Nile virus infections in recipients of blood transfusions.\n          Available at: http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5139a5.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b30","series-title":"N Engl J Med","first-page":"1236","article-title":"West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002.","volume":"349","author":"Pealer, L. N.","year":"2003","unstructured":"Pealer, L. N., A. A.Marfin, and L. R.Petersen. et al. West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002.N Engl J Med2003. 349:1236\u20131245."},{"key":"i1543-2165-131-5-719-b31","article-title":"Fact sheets. Blood safety and volunteer donations.","unstructured":"World Health Organization.\n          \n          Fact sheets. Blood safety and volunteer donations.\n          Available at: http:\/\/www.wpro.who.int\/media_centre\/fact_sheets\/fs_20040610.htm. Accessed November 25, 2006."},{"key":"i1543-2165-131-5-719-b32","series-title":"Lancet","first-page":"2151","article-title":"Blood supply and demand.","volume":"365","year":"2005","unstructured":"Blood supply and demand.\n          Lancet\n          2005. 365:2151."},{"key":"i1543-2165-131-5-719-b33","series-title":"Transfus Med Rev","first-page":"57","article-title":"Clearance of prions during plasma protein manufacture.","volume":"20","author":"Burdick, M. D.","year":"2006","unstructured":"Burdick, M. D., D. Y.Pifat, S. R. JrPetteway, and K.Cai. Clearance of prions during plasma protein manufacture.Transfus Med Rev2006. 20:57\u201362."},{"key":"i1543-2165-131-5-719-b34","article-title":"Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma.","unstructured":"World Health Organization.\n          \n          Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma.\n          Geneva, Switzerland: World Health Organization; 2004. WHO technical report, Series No. 924."},{"key":"i1543-2165-131-5-719-b35","series-title":"J Intern Med","first-page":"224","article-title":"Pathogen inactivation technology: cleansing the blood supply.","volume":"257","author":"Klein, H. G.","year":"2005","unstructured":"Klein, H. G.\n          \n          Pathogen inactivation technology: cleansing the blood supply.\n          J Intern Med\n          2005. 257:224\u2013237."},{"key":"i1543-2165-131-5-719-b36","series-title":"Transfusion","first-page":"1160","article-title":"The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.","volume":"39","author":"Tabor, E.","year":"1999","unstructured":"Tabor, E.\n          \n          The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.\n          Transfusion\n          1999. 39:1160\u20131168."},{"key":"i1543-2165-131-5-719-b37","series-title":"Biotechnol Appl Biochem","first-page":"141","article-title":"An adventure in biotechnology: the development of haemophilia A therapeutics\u2014from whole blood transfusion to recombinant DNA to gene therapy.","volume":"35","author":"Kingdon, H. S.","year":"2002","unstructured":"Kingdon, H. S. and R. L.Lundblad. An adventure in biotechnology: the development of haemophilia A therapeutics\u2014from whole blood transfusion to recombinant DNA to gene therapy.Biotechnol Appl Biochem2002. 35:141\u2013148."},{"key":"i1543-2165-131-5-719-b38","series-title":"Lancet","first-page":"1013","article-title":"Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform.","volume":"2","author":"Mannucci, P. M.","year":"1985","unstructured":"Mannucci, P. M., M.Colombo, and F.Rodeghiero. Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform.Lancet1985. 2:1013."},{"key":"i1543-2165-131-5-719-b39","series-title":"Ann Intern Med","first-page":"113","article-title":"Heated clotting factors and seroconversion for human immunodeficiency virus in three hemophilic patients.","volume":"107","author":"Mariani, G.","year":"1987","unstructured":"Mariani, G., A.Ghirardini, and F.Mandelli. et al. Heated clotting factors and seroconversion for human immunodeficiency virus in three hemophilic patients.Ann Intern Med1987. 107:113."},{"key":"i1543-2165-131-5-719-b40","series-title":"J Med Virol","first-page":"50","article-title":"Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.","volume":"30","author":"Skidmore, S. J.","year":"1990","unstructured":"Skidmore, S. J., K. J.Pasi, S. J.Mawson, M. D.Williams, and F. G.Hill. Serological evidence that dry heating of clotting factor concentrates prevents transmission of non-A, non-B hepatitis.J Med Virol1990. 30:50\u201352."},{"key":"i1543-2165-131-5-719-b41","series-title":"Am J Hematol","first-page":"228","article-title":"Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.","volume":"39","author":"Azzi, A.","year":"1992","unstructured":"Azzi, A., S.Ciappi, K.Zakvrzewska, M.Morfini, G.Mariani, and P. M.Mannucci. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates.Am J Hematol1992. 39:228\u2013230."},{"key":"i1543-2165-131-5-719-b42","series-title":"Am J Hematol","first-page":"142","article-title":"Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment.","volume":"35","author":"Rubinstein, A. I.","year":"1990","unstructured":"Rubinstein, A. I. and D. B.Rubinstein. Inability of solvent-detergent (S-D) treated factor VIII concentrate to inactivate parvoviruses and non-lipid enveloped non-A, non-B hepatitis virus in factor VIII concentrate: advantages to using sterilizing 100 degrees C dry heat treatment.Am J Hematol1990. 35:142."},{"key":"i1543-2165-131-5-719-b43","series-title":"Biologicals","first-page":"115","article-title":"Assessment of the viral safety of antivenoms fractionated from equine plasma.","volume":"32","author":"Burnouf, T.","year":"2004","unstructured":"Burnouf, T., E.Griffiths, A.Padilla, S.Seddik, M. A.Stephano, and J. M.Gutierrez. Assessment of the viral safety of antivenoms fractionated from equine plasma.Biologicals2004. 32:115\u2013128."},{"key":"i1543-2165-131-5-719-b44","series-title":"Transfus Clin Biol","first-page":"167","article-title":"Viral safety of intravenous immunoglobulins G for therapeutic use.","volume":"2","author":"Burnouf-Radosevich, M.","year":"1995","unstructured":"Burnouf-Radosevich, M.\n          \n          Viral safety of intravenous immunoglobulins G for therapeutic use.\n          Transfus Clin Biol\n          1995. 2:167\u2013179."},{"key":"i1543-2165-131-5-719-b45","series-title":"Transfusion","first-page":"866","article-title":"Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation.","volume":"36","author":"Omar, A.","year":"1996","unstructured":"Omar, A., C.Kempf, A.Immelmann, M.Rentsch, and J. J.Morgenthaler. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation.Transfusion1996. 36:866\u2013872."},{"key":"i1543-2165-131-5-719-b46","series-title":"Biologicals","first-page":"267","article-title":"Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.","volume":"26","author":"Bos, O. J.","year":"1998","unstructured":"Bos, O. J., D. G.Sunye, C. E.Nieuweboer, F. A.van Engelenburg, H.Schuitemaker, and J.Over. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.Biologicals1998. 26:267\u2013276."},{"key":"i1543-2165-131-5-719-b47","series-title":"Vox Sang","first-page":"75","article-title":"Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.","volume":"55","author":"Reid, K. G.","year":"1988","unstructured":"Reid, K. G., B.Cuthbertson, A. D.Jones, and R. V.McIntosh. Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products.Vox Sang1988. 55:75\u201380."},{"key":"i1543-2165-131-5-719-b48","series-title":"Lancet","first-page":"706","article-title":"Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.","volume":"1","author":"Prince, A. M.","year":"1986","unstructured":"Prince, A. M., B.Horowitz, and B.Brotman. Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.Lancet1986. 1:706\u2013710."},{"key":"i1543-2165-131-5-719-b49","series-title":"Transfusion","first-page":"102","article-title":"Current status of solvent\/detergent-treated frozen plasma.","volume":"38","author":"Klein, H. G.","year":"1998","unstructured":"Klein, H. G., R. Y.Dodd, and W. H.Dzik. et al. Current status of solvent\/detergent-treated frozen plasma.Transfusion1998. 38:102\u2013107."},{"key":"i1543-2165-131-5-719-b50","series-title":"Br J Haematol","first-page":"778","article-title":"Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura.","volume":"121","author":"Yarranton, H.","year":"2003","unstructured":"Yarranton, H., H.Cohen, S. R.Pavord, S.Benjamin, D.Hagger, and S. J.Machin. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura.Br J Haematol2003. 121:778\u2013785."},{"key":"i1543-2165-131-5-719-b51","series-title":"Transfusion","first-page":"1227","article-title":"A randomized trial of solvent\/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.","volume":"39","author":"Williamson, L. M.","year":"1999","unstructured":"Williamson, L. M., C. A.Llewelyn, and N. C.Fisher. et al. A randomized trial of solvent\/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.Transfusion1999. 39:1227\u20131234."},{"key":"i1543-2165-131-5-719-b52","series-title":"Transfusion","first-page":"2100","article-title":"A process for solvent\/detergent treatment of plasma for transfusion at blood centers using a disposable-bag system.","volume":"46","author":"Burnouf, T.","year":"2006","unstructured":"Burnouf, T., H. A.Goubran, M.Radosevich, M. A.Sayed, G.Gorgy, and M.El-Ekiaby. A process for solvent\/detergent treatment of plasma for transfusion at blood centers using a disposable-bag system.Transfusion2006. 46:2100\u20132108."},{"key":"i1543-2165-131-5-719-b53","series-title":"Haemophilia","first-page":"24","article-title":"Nanofiltration of plasma-derived biopharmaceutical products.","volume":"9","author":"Burnouf, T.","year":"2003","unstructured":"Burnouf, T. and M.Radosevich. Nanofiltration of plasma-derived biopharmaceutical products.Haemophilia2003. 9:24\u201337."},{"key":"i1543-2165-131-5-719-b54","series-title":"Vox Sang","first-page":"225","article-title":"Removal of small non-enveloped viruses by nanofiltration.","volume":"86","author":"Yokoyama, T.","year":"2004","unstructured":"Yokoyama, T., K.Murai, and T.Murozuka. et al. Removal of small non-enveloped viruses by nanofiltration.Vox Sang2004. 86:225\u2013229."},{"key":"i1543-2165-131-5-719-b55","series-title":"Transfus Med Rev","first-page":"61","article-title":"Virus inactivation in blood components by photoactive phenothiazine dyes.","volume":"16","author":"Wagner, S. J.","year":"2002","unstructured":"Wagner, S. J.\n          \n          Virus inactivation in blood components by photoactive phenothiazine dyes.\n          Transfus Med Rev\n          2002. 16:61\u201366."},{"key":"i1543-2165-131-5-719-b56","series-title":"Immunol Invest","first-page":"73","article-title":"Photodynamic virus inactivation of blood components.","volume":"24","author":"Mohr, H.","year":"1995","unstructured":"Mohr, H., B.Lambrecht, and A.Selz. Photodynamic virus inactivation of blood components.Immunol Invest1995. 24:73\u201385."},{"key":"i1543-2165-131-5-719-b57","series-title":"Transfusion","first-page":"1322","article-title":"Methylene blue treated fresh-frozen plasma: what is its contribution to blood safety?","volume":"43","author":"Williamson, L. M.","year":"2003","unstructured":"Williamson, L. M., R.Cardigan, and C. V.Prowse. Methylene blue treated fresh-frozen plasma: what is its contribution to blood safety?Transfusion2003. 43:1322\u20131329."},{"key":"i1543-2165-131-5-719-b58","series-title":"Transfus Apher Sci","first-page":"183","article-title":"Methylene blue and thionine in pathogen inactivation of plasma and platelet concentrates.","volume":"25","author":"Mohr, H.","year":"2001","unstructured":"Mohr, H.\n          \n          Methylene blue and thionine in pathogen inactivation of plasma and platelet concentrates.\n          Transfus Apher Sci\n          2001. 25:183\u2013184."},{"key":"i1543-2165-131-5-719-b59","series-title":"Blood Cells","first-page":"7","article-title":"Photochemical inactivation of viruses with psoralens: an overview.","volume":"18","author":"Hanson, C. V.","year":"1992","unstructured":"Hanson, C. V.\n          \n          Photochemical inactivation of viruses with psoralens: an overview.\n          Blood Cells\n          1992. 18:7\u201325."},{"key":"i1543-2165-131-5-719-b60","series-title":"Transfusion","first-page":"423","article-title":"Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.","volume":"37","author":"Lin, L.","year":"1997","unstructured":"Lin, L., D. N.Cook, and G. P.Wiesehahn. et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light.Transfusion1997. 37:423\u2013435."},{"key":"i1543-2165-131-5-719-b61","series-title":"Blood Cells","first-page":"57","article-title":"Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates.","volume":"18","author":"Corash, L.","year":"1992","unstructured":"Corash, L., L.Lin, and G.Wiesehahn. Use of 8-methoxypsoralen and long wavelength ultraviolet radiation for decontamination of platelet concentrates.Blood Cells1992. 18:57\u201373."},{"key":"i1543-2165-131-5-719-b62","series-title":"Blood Cells","first-page":"43","article-title":"Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet A light.","volume":"18","author":"Moroff, G.","year":"1992","unstructured":"Moroff, G., S.Wagner, L.Benade, and R. Y.Dodd. Factors influencing virus inactivation and retention of platelet properties following treatment with aminomethyltrimethylpsoralen and ultraviolet A light.Blood Cells1992. 18:43\u201354."},{"key":"i1543-2165-131-5-719-b63","series-title":"Vox Sang","first-page":"206","article-title":"Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats.","volume":"79","author":"van Rhenen, D. J.","year":"2000","unstructured":"van Rhenen, D. J., J.Vermeij, V.Mayaudon, C.Hind, L.Lin, and L.Corash. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats.Vox Sang2000. 79:206\u2013214."},{"key":"i1543-2165-131-5-719-b64","series-title":"Hum Exp Toxicol","first-page":"533","article-title":"Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets.","volume":"20","author":"Ciaravino, V.","year":"2001","unstructured":"Ciaravino, V., T.McCullough, and A. D.Dayan. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets.Hum Exp Toxicol2001. 20:533\u2013550."},{"key":"i1543-2165-131-5-719-b65","series-title":"Blood","first-page":"1534","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.","volume":"104","author":"McCullough, J.","year":"2004","unstructured":"McCullough, J., D. H.Vesole, and R. J.Benjamin. et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.Blood2004. 104:1534\u20131541."},{"key":"i1543-2165-131-5-719-b66","series-title":"Transfusion","first-page":"1443","article-title":"Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.","volume":"45","author":"Janetzko, K.","year":"2005","unstructured":"Janetzko, K., J. P.Cazenave, and H.Kluter. et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.Transfusion2005. 45:1443\u20131452."},{"key":"i1543-2165-131-5-719-b67","series-title":"Transfusion","first-page":"1864","article-title":"Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.","volume":"45","author":"Snyder, E.","year":"2005","unstructured":"Snyder, E., J.McCullough, and S. J.Slichter. et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial.Transfusion2005. 45:1864\u20131875."},{"key":"i1543-2165-131-5-719-b68","series-title":"Transfusion","first-page":"24","article-title":"Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.","volume":"46","author":"Murphy, S.","year":"2006","unstructured":"Murphy, S., E.Snyder, and R.Cable. et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light.Transfusion2006. 46:24\u201333."},{"key":"i1543-2165-131-5-719-b69","series-title":"Vox Sang","first-page":"171","article-title":"Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.","volume":"85","author":"Ciaravino, V.","year":"2003","unstructured":"Ciaravino, V., T.McCullough, G.Cimino, and T.Sullivan. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System.Vox Sang2003. 85:171\u2013182."},{"key":"i1543-2165-131-5-719-b70","series-title":"Transfusion","first-page":"1168","article-title":"Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.","volume":"46","author":"Sing, Y.","year":"2006","unstructured":"Sing, Y., L. S.Sawyer, and L. S.Pinkoski. et al. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function.Transfusion2006. 46:1168\u20131177."},{"key":"i1543-2165-131-5-719-b71","series-title":"Transfusion","first-page":"1302","article-title":"Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin.","volume":"42","author":"Hambleton, J.","year":"2002","unstructured":"Hambleton, J., D.Wages, and L.Radu-Radulescu. et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin.Transfusion2002. 42:1302\u20131307."},{"key":"i1543-2165-131-5-719-b72","series-title":"Transfusion","first-page":"1362","article-title":"Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.","volume":"45","author":"de Alarcon, P.","year":"2005","unstructured":"de Alarcon, P., R.Benjamin, and M.Dugdale. et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies.Transfusion2005. 45:1362\u20131372."},{"key":"i1543-2165-131-5-719-b73","series-title":"Blood","first-page":"3753","article-title":"Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.","volume":"107","author":"Mintz, P. D.","year":"2006","unstructured":"Mintz, P. D., N. M.Bass, and L. D.Petz. et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease.Blood2006. 107:3753\u20133760."},{"key":"i1543-2165-131-5-719-b74","series-title":"Transfusion","first-page":"30A","article-title":"vWF cleaving protease activity and inhibitors in patients with thrombotic thrombocytopenic purpura (TTP) treated with INTERCEPT FFP vs. conventional FFP: results of a phase III trial.","volume":"45","author":"Conlan, M. G.","year":"2005","unstructured":"Conlan, M. G., L.Corash, and J.Lin. et al. vWF cleaving protease activity and inhibitors in patients with thrombotic thrombocytopenic purpura (TTP) treated with INTERCEPT FFP vs. conventional FFP: results of a phase III trial.Transfusion2005. 45:30A."},{"key":"i1543-2165-131-5-719-b75","series-title":"Transfusion","first-page":"1693","article-title":"A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.","volume":"46","author":"Mintz, P. D.","year":"2006","unstructured":"Mintz, P. D., A.Neff, and M.MacKenzie. et al. A randomized, controlled phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.Transfusion2006. 46:1693\u20131704."},{"key":"i1543-2165-131-5-719-b76","series-title":"Transfusion","first-page":"63s","article-title":"Preparation of cryoprecipitate from photochemically treated fresh frozen plasma.","volume":"40","author":"Mintz, P. D.","year":"2000","unstructured":"Mintz, P. D., N. L.Avery, and S. L.Monlaison. et al. Preparation of cryoprecipitate from photochemically treated fresh frozen plasma.Transfusion2000. 40:63s."},{"key":"i1543-2165-131-5-719-b77","series-title":"Transfusion","first-page":"1453","article-title":"Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.","volume":"45","author":"Yarranton, H.","year":"2005","unstructured":"Yarranton, H., A. S.Lawrie, I. J.Mackie, L.Pinkoski, L.Corash, and S. J.Machin. Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.Transfusion2005. 45:1453\u20131458."},{"key":"i1543-2165-131-5-719-b78","series-title":"Photochem Photobiol","first-page":"561","article-title":"Binding affinities of commonly employed sensitizers of viral inactivation.","volume":"75","author":"Dardare, N.","year":"2002","unstructured":"Dardare, N. and M. S.Platz. Binding affinities of commonly employed sensitizers of viral inactivation.Photochem Photobiol2002. 75:561\u2013564."},{"key":"i1543-2165-131-5-719-b79","series-title":"Photochem Photobiol","first-page":"609","article-title":"Separation, identification and quantification of riboflavin and its photoproducts in blood products using HPLC with fluorescence detection: a method to support pathogen reduction technology.","volume":"80","author":"Hardwick, C. C.","year":"2004","unstructured":"Hardwick, C. C., T. R.Herivel, S. C.Hernandez, P. H.Ruane, and R. P.Goodrich. Separation, identification and quantification of riboflavin and its photoproducts in blood products using HPLC with fluorescence detection: a method to support pathogen reduction technology.Photochem Photobiol2004. 80:609\u2013615."},{"key":"i1543-2165-131-5-719-b80","article-title":"Vitamin B,.","unstructured":"US Food and Drug Administration.\n          \n          Vitamin B,.\n          21 CFR 582.5695 (1998)."},{"key":"i1543-2165-131-5-719-b81","series-title":"Transfusion","first-page":"877","article-title":"Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.","volume":"44","author":"Ruane, P. H.","year":"2004","unstructured":"Ruane, P. H., R.Edrich, D.Gampp, S. D.Keil, R. L.Leonard, and R. P.Goodrich. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.Transfusion2004. 44:877\u2013885."},{"key":"i1543-2165-131-5-719-b82","series-title":"Vox Sang","first-page":"211","article-title":"The use of riboflavin for the inactivation of pathogens in blood products.","volume":"78","author":"Goodrich, R. P.","year":"2000","unstructured":"Goodrich, R. P.\n          \n          The use of riboflavin for the inactivation of pathogens in blood products.\n          Vox Sang\n          2000. 78:(S2). 211\u2013215."},{"key":"i1543-2165-131-5-719-b83","series-title":"Transfus Apher Sci","first-page":"189","article-title":"Use of riboflavin for photoinactivation of pathogens in blood components.","volume":"25","author":"Schuyler, R.","year":"2001","unstructured":"Schuyler, R.\n          \n          Use of riboflavin for photoinactivation of pathogens in blood components.\n          Transfus Apher Sci\n          2001. 25:189\u2013190."},{"key":"i1543-2165-131-5-719-b84","series-title":"Vox Sang","first-page":"85","article-title":"Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.","volume":"90","author":"Cardo, L. J.","year":"2006","unstructured":"Cardo, L. J., F. J.Rentas, and L.Ketchum. et al. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.Vox Sang2006. 90:85\u201391."},{"key":"i1543-2165-131-5-719-b85","series-title":"Transfusion","first-page":"1750","article-title":"Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage.","volume":"45","author":"Li, J.","year":"2005","unstructured":"Li, J., L.Goodrich, E.Hansen, R.Edrich, D.Gampp, and R. P.Goodrich. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage.Transfusion2005. 45:1750\u20131758."},{"key":"i1543-2165-131-5-719-b86","series-title":"Vox Sang","first-page":"183s","article-title":"Mirasol pathogen reduction treated fresh frozen plasma maintains protein quality.","volume":"91","author":"Buytaert-Hoefen, K. A.","year":"2006","unstructured":"Buytaert-Hoefen, K. A., D.Gampp, R.Edrich, and R.Goodrich. Mirasol pathogen reduction treated fresh frozen plasma maintains protein quality.Vox Sang2006. 91:183s."},{"key":"i1543-2165-131-5-719-b87","series-title":"Transfus Apher Sci","first-page":"179","article-title":"Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.","volume":"25","author":"Corash, L.","year":"2001","unstructured":"Corash, L.\n          \n          Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application.\n          Transfus Apher Sci\n          2001. 25:179\u2013181."},{"key":"i1543-2165-131-5-719-b88","series-title":"Transfus Clin Biol","first-page":"138","article-title":"Inactivation of infectious pathogens in labile blood components: meeting the challenge.","volume":"8","author":"Corash, L.","year":"2001","unstructured":"Corash, L.\n          \n          Inactivation of infectious pathogens in labile blood components: meeting the challenge.\n          Transfus Clin Biol\n          2001. 8:138\u2013145."},{"key":"i1543-2165-131-5-719-b89","series-title":"Transfusion","first-page":"1739","article-title":"Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients.","volume":"45","author":"Benjamin, R. J.","year":"2005","unstructured":"Benjamin, R. J., J.McCullough, and P. D.Mintz. et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients.Transfusion2005. 45:1739\u20131749."},{"key":"i1543-2165-131-5-719-b90","series-title":"Blood","first-page":"130a","article-title":"Antibodies to S-303 treated red blood cells prepared with the original treatment process for pathogen inactivation do not react with red blood cells prepared with a modified S-303 treatment process.","volume":"106","author":"Conlan, M. G.","year":"2005","unstructured":"Conlan, M. G., G.Garrity, and G.Castro. et al. Antibodies to S-303 treated red blood cells prepared with the original treatment process for pathogen inactivation do not react with red blood cells prepared with a modified S-303 treatment process.Blood2005. 106:130a."},{"key":"i1543-2165-131-5-719-b91","series-title":"Transfusion","first-page":"1308","article-title":"Inactivation of HIV in blood.","volume":"42","author":"Ohagen, A.","year":"2002","unstructured":"Ohagen, A., V.Gibaja, S.Aytay, J.Horrigan, D.Lunderfille, and A.Lazo. Inactivation of HIV in blood.Transfusion2002. 42:1308\u20131317."},{"key":"i1543-2165-131-5-719-b92","series-title":"Transfusion","first-page":"1029","article-title":"West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation.","volume":"43","author":"Mather, T.","year":"2003","unstructured":"Mather, T., T.Takeda, and J.Tassello. et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation.Transfusion2003. 43:1029\u20131037."},{"key":"i1543-2165-131-5-719-b93","series-title":"Transfusion","first-page":"139","article-title":"Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies.","volume":"42","author":"Purmal, A.","year":"2002","unstructured":"Purmal, A., C. R.Valeri, and W.Dzik. et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies.Transfusion2002. 42:139\u2013145."},{"key":"i1543-2165-131-5-719-b94","series-title":"Vox Sang","first-page":"313","article-title":"Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry.","volume":"83","author":"Lazo, A.","year":"2002","unstructured":"Lazo, A., J.Tassello, and V.Jayarama. et al. Broad-spectrum virus reduction in red cell concentrates using INACTINE PEN110 chemistry.Vox Sang2002. 83:313\u2013323."},{"key":"i1543-2165-131-5-719-b95","series-title":"Vox Sang","first-page":"1","article-title":"Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.","volume":"87","author":"Ohagen, A.","year":"2004","unstructured":"Ohagen, A., V.Gibaja, and J.Horrigan. et al. Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110.Vox Sang2004. 87:1\u20139."},{"key":"i1543-2165-131-5-719-b96","series-title":"Transfusion","first-page":"731","article-title":"Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry.","volume":"44","author":"Zavizion, B.","year":"2004","unstructured":"Zavizion, B., M.Pereira, and J. M.de Melo. et al. Inactivation of protozoan parasites in red blood cells using INACTINE PEN110 chemistry.Transfusion2004. 44:731\u2013738."},{"key":"i1543-2165-131-5-719-b97","series-title":"Transfusion","first-page":"286","article-title":"Inactivation of mycoplasma species in blood by INACTINE PEN110 process.","volume":"44","author":"Zavizion, B.","year":"2004","unstructured":"Zavizion, B., A.Purmal, J.Chapman, and B.Alford. Inactivation of mycoplasma species in blood by INACTINE PEN110 process.Transfusion2004. 44:286\u2013293."},{"key":"i1543-2165-131-5-719-b98","series-title":"Transfusion","first-page":"135","article-title":"Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.","volume":"43","author":"Zavizion, B.","year":"2003","unstructured":"Zavizion, B., D.Serebryanik, I.Serebryanik, J.Chapman, and A.Purmal. Prevention of Yersinia enterocolitica, Pseudomonas fluorescens, and Pseudomonas putida outgrowth in deliberately inoculated blood by a novel pathogen-reduction process.Transfusion2003. 43:135\u2013142."},{"key":"i1543-2165-131-5-719-b99","series-title":"Transfusion","first-page":"146","article-title":"Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a phase I clinical study.","volume":"42","author":"AuBuchon, J. P.","year":"2002","unstructured":"AuBuchon, J. P., C. A.Pickard, and L. H.Herschel. et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a phase I clinical study.Transfusion2002. 42:146\u2013152."},{"key":"i1543-2165-131-5-719-b100","series-title":"Transfus Med Rev","first-page":"61","article-title":"Virus inactivation in blood components by photoactive phenothiazine dyes.","volume":"16","author":"Wagner, S. J.","year":"2002","unstructured":"Wagner, S. J.\n          \n          Virus inactivation in blood components by photoactive phenothiazine dyes.\n          Transfus Med Rev\n          2002. 16:61\u201366."},{"key":"i1543-2165-131-5-719-b101","series-title":"Dev Biol Stand","first-page":"125","article-title":"The use of dimethylmethylene blue for virus photoinactivation of red cell suspensions.","volume":"102","author":"Wagner, S. J.","year":"2000","unstructured":"Wagner, S. J., A.Skripchenko, and D.Robinette. et al. The use of dimethylmethylene blue for virus photoinactivation of red cell suspensions.Dev Biol Stand2000. 102:125\u2013129."},{"key":"i1543-2165-131-5-719-b102","series-title":"Transfusion","first-page":"968","article-title":"Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB.","volume":"40","author":"Skripchenko, A. A.","year":"2000","unstructured":"Skripchenko, A. A. and S. J.Wagner. Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB.Transfusion2000. 40:968\u2013975."},{"key":"i1543-2165-131-5-719-b103","series-title":"Transfusion","first-page":"729","article-title":"Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue.","volume":"38","author":"Wagner, S. J.","year":"1998","unstructured":"Wagner, S. J., A.Skripchenko, D.Robinette, D. A.Mallory, and L.Cincotta. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue.Transfusion1998. 38:729\u2013737."},{"key":"i1543-2165-131-5-719-b104","series-title":"Vox Sang","first-page":"183","article-title":"Composition of the additive solution affects red blood cell integrity after photodynamic treatment.","volume":"85","author":"Besselink, G. A. J.","year":"2003","unstructured":"Besselink, G. A. J., I. G.Ebbing, P. M.Hilarius, D.de Korte, A. J.Verhoeven, and J. W. M.Lagerberg. Composition of the additive solution affects red blood cell integrity after photodynamic treatment.Vox Sang2003. 85:183\u2013189."},{"key":"i1543-2165-131-5-719-b105","series-title":"Transfusion","first-page":"752","article-title":"Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties.","volume":"45","author":"Wagner, S. J.","year":"2005","unstructured":"Wagner, S. J., A.Skripchenko, L.Cincotta, D.Thompson-Montgomery, and H.Awatefe. Use of a flexible thiopyrylium photosensitizer and competitive inhibitor for pathogen reduction of viruses and bacteria with retention of red cell storage properties.Transfusion2005. 45:752\u2013760."},{"key":"i1543-2165-131-5-719-b106","series-title":"Transfusion","first-page":"213","article-title":"Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties.","volume":"46","author":"Skripchenko, A.","year":"2006","unstructured":"Skripchenko, A., S. J.Wagner, D.Thompson-Montgomery, and H.Awatefe. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties.Transfusion2006. 46:213\u2013219."},{"key":"i1543-2165-131-5-719-b107","series-title":"Lancet","first-page":"529","article-title":"Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood.","volume":"364","author":"Gregori, L.","year":"2004","unstructured":"Gregori, L., N.McCombie, and D.Palmer. et al. Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood.Lancet2004. 364:529\u2013531."},{"key":"i1543-2165-131-5-719-b108","series-title":"Transfusion","first-page":"1839","article-title":"Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.","volume":"45","author":"Sowemimo-Coker, S.","year":"2005","unstructured":"Sowemimo-Coker, S., R.Kascsak, and A.Kim. et al. Removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leukoreduction filter.Transfusion2005. 45:1839\u20131844."},{"key":"i1543-2165-131-5-719-b109","series-title":"Semin Hematol","first-page":"27","article-title":"Inactivation of cytomegalovirus in platelet concentrates using Helinx technology.","volume":"38","author":"Lin, L.","year":"2001","unstructured":"Lin, L.\n          \n          Inactivation of cytomegalovirus in platelet concentrates using Helinx technology.\n          Semin Hematol\n          2001. 38:(4S11). 27\u201333."},{"key":"i1543-2165-131-5-719-b110","series-title":"Transfusion","first-page":"1496","article-title":"Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.","volume":"44","author":"Lin, L.","year":"2004","unstructured":"Lin, L., R.Dikeman, and B.Molini. et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria.Transfusion2004. 44:1496\u20131504."},{"key":"i1543-2165-131-5-719-b111","series-title":"Vox Sang","first-page":"209","article-title":"Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function.","volume":"78","author":"Knutson, F.","year":"2000","unstructured":"Knutson, F., R.Alfonso, and K.Dupuis. et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function.Vox Sang2000. 78:209\u2013216."},{"key":"i1543-2165-131-5-719-b112","series-title":"Transfus Med Rev","first-page":"45","article-title":"The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.","volume":"20","author":"Roback, J. D.","year":"2006","unstructured":"Roback, J. D., M.Conlan, W. L.Drew, P.Ljungman, W. G.Nichols, and J. K.Preiksaitis. The role of photochemical treatment with amotosalen and UV-A light in the prevention of transfusion-transmitted cytomegalovirus infections.Transfus Med Rev2006. 20:45\u201356."},{"key":"i1543-2165-131-5-719-b113","series-title":"Transfusion","first-page":"1459","article-title":"Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.","volume":"45","author":"Eastman, R. T.","year":"2005","unstructured":"Eastman, R. T., L. K.Barrett, K.Dupuis, F. S.Buckner, and W. C.Van Voorhis. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.Transfusion2005. 45:1459\u20131463."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/131\/5\/article-p719.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/131\/5\/719\/2762645\/1543-2165(2007)131%255b719_pitdsf%255d2_0_co_2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/131\/5\/article-p719.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/131\/5\/article-p719.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:00:22Z","timestamp":1770771622000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/131\/5\/article-p719.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":226,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5858\/2007-131-719-pitdsf","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}